Association between body mass index at diagnosis and pediatric leukemia mortality and relapse: A systematic review and meta-Analysis

Leukemia and Lymphoma

Volumn 57, Issue 5, 2016, Pages 1140-1148

  Amankwah, Ernest K ^a,b   Saenz, Ashleigh M ^c   Hale, Gregory A ^a,b   Brown, Patrick A ^b  

^a JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Body mass index; mortality and relapse; obesity; pediatric acute leukemia

Indexed keywords

ACUTE LEUKEMIA; BODY MASS; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; DISEASE ASSOCIATION; EMBASE; EVENT FREE SURVIVAL; HUMAN; LEUKEMIA RELAPSE; MEDLINE; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PUBLISHING; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; ADOLESCENT; CHILD; COMPLICATION; FEMALE; INFANT; LEUKEMIA; MALE; MORTALITY; NEWBORN; OBESITY; PATHOLOGY; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE;

ADOLESCENT; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA; MALE; MORTALITY; OBESITY; PROPORTIONAL HAZARDS MODELS; PUBLICATION BIAS; RECURRENCE;

EID: 84949771352     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1076815     Document Type: Review

References (57)

1. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 766-781.
2. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014; 311: 806-814.
3. Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 2006; 98: 1204-1214.
4. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638.
5. Campbell PT, Newton CC, Dehal AN, et al. Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 2012; 30: 42-52.
6. Canlorbe G, Bendifallah S, Raimond E, et al. Severe obesity impacts recurrence-free survival of women with high-risk endometrial cancer: results of a French Multicenter Study. Ann Surg Oncol 2015; 22: 2714-2721.
7. Cantarutti A, Bonn SE, Adami HO., et al. Body Mass Index and mortality in men with prostate cancer. Prostate 2015; 75: 1129-1136
8. Jiralerspong S, Kim ES, Dong W, et al. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol Off J ESMO 2013; 24: 2506-2514.
9. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol 2004; 22: 648-657.
10. Parekh N, Chandran U, Bandera EV. Obesity in cancer survival. Annu Rev Nutr 2012; 32: 311-342.
11. Taghizadeh N, Boezen HM, Schouten JP, et al. BMI and lifetime changes in BMI and Cancer Mortality Risk. PLoS One 2015; 10: e0125261.
12. Mezei G, Sudan M, Izraeli S, et al. Epidemiology of childhood leukemia in the presence and absence of Down syndrome. Cancer Epidemiol 2014; 38: 479-489.
13. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet 2013; 381: 1943-1955.
14. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030-1043.
15. Butturini AM, Dorey FJ, Lange BJ, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol 2007; 25: 2063-2069.
16. Gelelete CB, Pereira SH, Azevedo AM, et al. Overweight as a prognostic factor in children with acute lymphoblastic leukemia. Obesity (Silver Spring) 2011; 19: 1908-1911.
17. Lange BJ, Gerbing RB, Feusner J, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 2005; 293: 203-211.
18. Orgel E, Sposto R, Malvar J, et al. Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol 2014; 32: 1331-1337.
19. Orgel E, Tucci J, Alhushki W, et al. Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. Blood 2014; 124: 3932-3938.
20. Aplenc R, Zhang MJ, Sung L, et al. Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. Blood 2014; 123: 3504-3511.
21. Baillargeon J, Langevin AM, Lewis M, et al. Obesity and survival in a cohort of predominantly hispanic children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2006; 28: 575-578.
22. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. BMJ 2009; 339: b2535.
23. Wells GA SB, OConnell D, Peterson J., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-Analyses; 2005. Available from: http://www.ohri.ca/programs/clinical-epidemiology/oxford.htm [last accessed 15 May 2015].
24. Levin ML. The occurence of lung cancer in man. Acta Un Intern Cancer 1953; 9: 531-541.
25. Breccia M, Mazzarella L, Bagnardi V, et al. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood 2012; 119: 49-54.
26. Navarro WH, Agovi MA, Logan BR, et al. Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults. Biol Blood Marrow Transplant 2010; 16: 1442-1450.
27. Lee JH, Rademaker AW, Powell BL, et al. Obesity does not affect the recurrence free survival rates in children less than 20 years of age in acute promyelocytic leukemia (APL). Blood 2014; 124: 957.
28. Bang KW, Seo SY, Lee JW, et al. Evaluation of changes in random blood glucose and body mass index during and after completion of chemotherapy in children with acute lymphoblastic leukemia. Korean J Pediatr 2012; 55: 121-127.
29. Matsuzaki A, Ishii E, Nagatoshi Y, et al. Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group. Int J Hematol 2001; 73: 369-377.
30. Myers LC, Sun P, Brennan LL, et al. Effect of weight on outcomes of children undergoing hematopoietic cell transplantation. Pediatr Hematol Oncol. 2013; 30: 116-130.
31. Oakhill A, Mann JR. Poor prognosis of acute lymphoblastic leukaemia in Asian children living in the United Kingdom. Br Med J (Clin Res Ed) 1983; 286: 839-841.
32. Reisi N, Azhir A, Hashemipour M, et al. The metabolic syndrome in survivors of childhood acute lymphoblastic leukemia in Isfahan, Iran. J Res Med Sci 2009; 14: 111-116.
33. Baillargeon J, Langevin AM, Lewis M, et al. Therapy-related changes in body size in hispanic children with acute lymphoblastic leukemia. Cancer 2005; 103: 1725-1729.
34. Tonorezos ES, Vega GL, Sklar CA, et al. Adipokines, body fatness, and insulin resistance among survivors of childhood leukemia. Pediatr Blood Cancer 2012; 58: 31-36.
35. Karakaya P, Yilmaz S, Tufekci O, et al. Endocrinological and cardiological late effects among survivors of childhood acute lymphoblastic leukemia. Turk J Hematol 2013; 30: 290-299.
36. White M, Murphy AJ, Hallahan A, et al. Survival in overweight and underweight children undergoing hematopoietic stem cell transplantation. Eur J Clin Nutr 2012; 66: 1120-1123.
37. Aldhafiri FK, McColl JH, Reilly JJ. Prognostic significance of being overweight and obese at diagnosis in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2014; 36: 234-236.
38. Karakurt H, Sarper N, Kilic SC, et al. Screening survivors of childhood acute lymphoblastic leukemia for obesity, metabolic syndrome, and insulin resistance. Pediatr Hematol Oncol 2012; 29: 551-561.
39. Reilly JJ, Odame I, McColl JH, et al. Does weight for height have prognostic significance in children with acute lymphoblastic leukemia? Am J Pediatr Hematol Oncol 1994; 16: 225-230.
40. Shanta V, Maitreyan V, Sagar TG, et al. Prognostic variables and survival in pediatric acute lymphoblastic leukemias: Cancer Institute experience. Pediatr Hematol Oncol 1996; 13: 205-216.
41. Ethier MC, Alexander S, Abla O, et al. Association between obesity at diagnosis and weight change during induction and survival in pediatric acute lymphoblastic leukemia. Leuk Lymphoma 2012; 53: 1677-1681.
42. Surapolchai P, Pakakasama S, Sirachainan N, et al. Comparative outcomes of Thai children with acute lymphoblastic leukemia treated with two consecutive protocols: 11-year experience. Leuk Lymphoma 2012; 53: 891-900.
43. Bulley S, Gassas A, Dupuis LL, et al. Inferior outcomes for overweight children undergoing allogeneic stem cell transplantation. Br J Haematol 2008; 140: 214-217.
44. Canner J, Alonzo TA, Franklin J, et al. Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group. Cancer 2013; 119: 4162-4169.
45. Rogers PC, Meacham LR, Oeffinger KC, et al. Obesity in pediatric oncology. Pediatr Blood Cancer 2005; 45: 881-891.
46. Meeske KA, Siegel SE, Globe DR, et al. Prevalence and correlates of fatigue in long-term survivors of childhood leukemia. J Clin Oncol 2005; 23: 5501-5510.
47. Schmitz KH, Neuhouser ML, Agurs-Collins T, et al. Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity. J Nati Cancer Inst 2013; 105: 1344-1354.
48. Browning B, Thormann K, Donaldson A, et al. Busulfan dosing in children with BMIs >/= 85% undergoing HSCT: a new optimal strategy. Biol Blood Marrow Transplant 2011; 17: 1383-1388.
49. Dupuis LL, Najdova M, Saunders EF. Retrospective appraisal of busulfan dose adjustment in children. Bone Marrow Transplant 2000; 26: 1143-1147.
50. Veal GJ, Cole M, Errington J, et al. Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. Clin Cancer Res 2005; 11: 5893-5899.
51. Zuccaro P, Guandalini S, Pacifici R, et al. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Therapeut Drug Monit 1991; 13: 37-41.
52. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000; 39: 215-231.
53. Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 2005; 23: 3376-3382.
54. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430.
55. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011; 11: 886-895.
56. Nieman KM, Romero IL, Van Houten B, et al. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta 2013; 1831: 1533-1541.
57. Park J, Morley TS, Kim M, et al. Obesity and cancer-mechanisms underlying tumor progression and recurrence. Nat Rev Endocrinol 2014; 10: 455-465.